| 18454-9 |
Dodecenoylcarnitine (C12:1) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Dodecenoylcarnitine (C12:1) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18454-9 |
|
|
|
|
Observation |
|
|
|
0 |
Dodecenoylcarn SerPl-mCnc |
|
|
|
Y |
|
C12:1; Chemistry; i; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18455-6 |
Dodecanoylcarnitine (C12) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Dodecanoylcarnitine (C12) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18455-6 |
|
|
|
|
Observation |
|
|
|
0 |
Dodecanoylcarn SerPl-mCnc |
|
|
|
Y |
|
C12; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18456-4 |
Tetradecadienoylcarnitine (C14:2) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Tetradecadienoylcarnitine (C14:2) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18456-4 |
|
|
|
|
Observation |
|
|
|
0 |
Tdecadienoylcarn SerPl-mCnc |
|
|
|
Y |
|
C14:2; Chemistry; II; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tdecadienoylcarn |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18457-2 |
Tetradecenoylcarnitine (C14:1) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Tetradecenoylcarnitine (C14:1) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18457-2 |
|
|
|
|
Observation |
|
|
|
0 |
Tdecenoylcarn SerPl-mCnc |
|
|
|
Y |
|
C14:1; Chemistry; i; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tdecenoylcarn |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18458-0 |
3-Hydroxytetradecadienoylcarnitine (C14:2-OH) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18458-0 |
|
|
|
|
Observation |
|
|
|
0 |
3OH-Tdecadienoylcar SerPl-mCnc |
|
|
|
Y |
|
3-hydroxy-tetradecadienoylcarnitine; 3OH-Tdecadienoylcar; C14:2OH; Chemistry; II; III; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18459-8 |
3-Hydroxytetradecenoylcarnitine (C14:1-OH) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18459-8 |
|
|
|
|
Observation |
|
|
|
0 |
3OH-Tdecenoylcarn SerPl-mCnc |
|
|
|
Y |
|
3-hydroxy-tetradecenoylcarnitine; 3OH-Tdecenoylcarn; C14:1OH; C14:1-OH; Chemistry; i; III; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 1846-5 |
Amylo-alpha-1,6-glucosidase |
CCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Amylo-alpha-1,6-glucosidase [Enzymatic activity/volume] in Red Blood Cells |
|
NAM |
DefinitionDescription |
|
|
U/mL RBC |
|
|
|
|
|
|
CHEM |
|
1846-5 |
|
|
|
|
Both |
|
|
|
0 |
AGL RBC-cCnc |
|
|
|
Y |
|
A1; AGL; Alfa; Amylo-1,6-glucosidase; Catalytic Concentration; Chemistry; Erythrocytes; Glucoinvertase; Glucosidosucrase; i; Maltase; Maltase-glucoamylase; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles |
2.54 |
1 |
|
|
|
|
|
|
|
U/mL{RBCs} |
|
|
|
0 |
| 18460-6 |
Palmitoylcarnitine (C16) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Palmitoylcarnitine (C16) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18460-6 |
|
|
|
|
Observation |
|
|
|
0 |
Palmitoylcarn SerPl-mCnc |
|
|
|
Y |
|
C16; Chemistry; Hexadecanoylcarnitine; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18461-4 |
3-Hydroxypalmitoylcarnitine (C16-OH) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
3-Hydroxypalmitoylcarnitine (C16-OH) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18461-4 |
|
|
|
|
Observation |
|
|
|
0 |
3OH-Palmitoylcarn SerPl-mCnc |
|
|
|
Y |
|
3-hydroxyhexadecanoylcarnitine; 3-hydroxy-hexadecanoylcarnitine; 3-hydroxy-palmitoylcarnitine; 3OH-Palmitoylcarn; C16OH; C16-OH; Chemistry; III; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18462-2 |
Linoleoylcarnitine (C18:2) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Linoleoylcarnitine (C18:2) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18462-2 |
|
|
|
|
Observation |
|
|
|
0 |
Linoleoylcarn SerPl-mCnc |
|
|
|
Y |
|
C18:2; Chemistry; II; Level; Linoleylcarnitine; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18463-0 |
Oleoylcarnitine (C18:1) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Oleoylcarnitine (C18:1) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18463-0 |
|
|
|
|
Observation |
|
|
|
0 |
Oleoylcarn SerPl-mCnc |
|
|
|
Y |
|
C18:1; Chemistry; i; Level; Mass concentration; Octadecenoyl carnitine; Octadecenoylcarnitine; Oleoyl carnitine; Oleyl carnitine; Oleylcarnitine; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18464-8 |
3-Hydroxylinoleoylcarnitine (C18:2-OH) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
3-Hydroxylinoleoylcarnitine (C18:2-OH) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18464-8 |
|
|
|
|
Observation |
|
|
|
0 |
3OH-Linoleoylcarn SerPl-mCnc |
|
|
|
Y |
|
3-hydroxy-linoleoylcarnitine; 3-hydroxylinoleylcarnitine; 3OH-Linoleoylcarn; C18:2OH; C18:2-OH; Chemistry; II; III; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18465-5 |
3-Hydroxyoleoylcarnitine (C18:1-OH) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
3-Hydroxyoleoylcarnitine (C18:1-OH) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18465-5 |
|
|
|
|
Observation |
|
|
|
0 |
3OH-Oleoylcarn SerPl-mCnc |
|
|
|
Y |
|
3-hydroxy-oleoylcarnitine; 3-hydroxyoleylcarnitine; 3OH-Oleoylcarn; C18:1OH; C18:1-OH; Chemistry; i; III; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18466-3 |
Dicarboxyoleylcarnitine (C18:1-DC) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Dicarboxyoleylcarnitine (C18:1-DC) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18466-3 |
|
|
|
|
Observation |
|
|
|
0 |
Dicarboxyoleylcarn SerPl-mCnc |
|
|
|
Y |
|
C18:1DC; C18:1-DC; Chemistry; Dicarboxylic carnitine; Dicarboxyoleoylcarnitine; i; Level; Mass concentration; Octadecenediolcarnitine; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 18467-1 |
Venlafaxine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Venlafaxine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
18467-1 |
|
|
|
|
Both |
|
|
|
0 |
Venlafaxine Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Efexor; Effexor; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Venlafaxin |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 18468-9 |
Aspergillus fumigatus Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Aspergillus fumigatus Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18468-9 |
|
|
|
|
Both |
|
|
|
0 |
A fumigatus Ab CSF Ql |
|
|
|
|
|
A fumigatus; ABS; Aby; Antby; Anti; Antibodies; Antibody; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Farmers lung; Fum; ID; Infectious Disease; InfectiousDisease; m003; m3; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18469-7 |
Methyclothiazide |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Methyclothiazide [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
18469-7 |
|
|
|
|
Both |
|
|
|
0 |
Methyclothiazide SerPl-mCnc |
|
|
|
Y |
|
2-methyl-3-chloromethylhydrochlorothiazide; Aquatensen; C9H11Cl2N3O4S2; DRUG/TOXICOLOGY; Drugs; Enduron; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.44 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 1847-3 |
Amyloid associated protein |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Amyloid associated protein [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
1847-3 |
|
|
|
|
Both |
|
|
|
0 |
AA Prot Ser-mCnc |
|
|
|
Y |
|
AA Prot; AAP; Assoc; Chemistry; Level; Mass concentration; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random; SAA; Serum; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 18470-5 |
Norclomipramine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Norclomipramine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
18470-5 |
|
|
|
|
Both |
|
|
|
0 |
Norclomipramine Ur-mCnc |
|
|
|
Y |
|
Clomipramine metabolite; Desmeth; Desmethylclomip; Desmethylclomipramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 18471-3 |
Metoclopramide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Metoclopramide [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
18471-3 |
|
|
|
|
Both |
|
|
|
0 |
Metoclopramide Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Reglan; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 18472-1 |
Organophosphate pesticides |
Prid |
Urine |
Pt |
Nom |
|
|
ACTIVE |
Organophosphate pesticides [Identifier] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
18472-1 |
|
|
|
|
Both |
|
|
|
0 |
OP Pesticides Ur |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; OP Pesticides; Point in time; Random; UA; UR; Urn |
2.19 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 18473-9 |
HYDROmorphone |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
HYDROmorphone [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
18473-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
HYDROmorphone Ur Ql Cfm |
|
|
|
|
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dihydromorphinone; Dilaudid; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Hydromorphinone; Illicit; LC/MS/MS; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18474-7 |
HER2 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
HER2 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
18474-7 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
Her2 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; C-ERBB-2; erb; ERB2; ERB-2; erbB2; HER-2; HER-2/neu; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Oncology; Ordinal; Pathology; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18475-4 |
Phenylalanine/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Phenylalanine/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/mol creatinine |
|
|
|
|
|
|
CHEM |
|
18475-4 |
|
|
|
|
Observation |
|
|
|
0 |
Phe/Creat Ur-sRto |
|
|
|
Y |
|
Chemistry; CR; Crea; Creat; Phe; Point in time; PPA; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
mmol/mol{creat} |
|
|
|
0 |
| 18476-2 |
Uroporphyrinogen decarboxylase |
PrThr |
RBC |
Pt |
Ord |
|
|
ACTIVE |
Uroporphyrinogen decarboxylase [Presence] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
18476-2 |
|
|
|
|
Both |
|
|
|
0 |
URO-D RBC Ql |
|
|
|
|
|
Chemistry; Erythrocytes; Hematology; Heme; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Red blood cells; Red blood corpusles; Screen; Upg D; UPGD; URO; URO-D; Urophorph; Uroporhngn; Uroporphrg |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
